BioCentury
ARTICLE | Clinical News

Anagrelide CR regulatory update

December 30, 2016 9:10 PM UTC

Galena said FDA confirmed that a Phase III trial comparing anagrelide CR vs. best available therapy in patients with essential thrombocythemia would be appropriate for an NDA submission using the 505(...

BCIQ Company Profiles

Galena Biopharma Inc.